Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A collaborative study led by the OPDC's Dr Nora Bengoa-Vergniory has shown that compounds known as molecular tweezers could become a promising disease modifying therapy for Parkinson’s.

None

A team of researchers has shown that tiny compounds known as molecular “tweezers” could become a promising therapy to slow Parkinson’s. This new kind of drug works by pulling apart toxic clumps of protein that form in the brain during Parkinson’s.

The therapy has previously shown high potential for targeting toxic protein clumps that form in neurodegenerative conditions such as Alzheimer’s. The research teams therefore investigated whether a particular molecular tweezer, CLR01, was able to reduce formation of protein clumps in cell and mouse models of Parkinson’s.

The research was led by the Oxford Parkinson’s Disease Centre at the University of Oxford, created through funding from Parkinson’s UK, and supported by the Medical Research Council with collaborators from the University of Bordeaux, the Universidad del País Vasco and the University of California.

The study showed that CLR01 is able to decrease clusters of the Parkinson’s protein alpha-synuclein forming and prevent the death of human neurons that were made from stem cells.

Researchers tested CLR01 in a mouse model of Parkinson’s that stimulates the formation of protein clusters and mimics the motor symptoms experienced by people with the condition, which can include tremor and slowness of movement. As the mice aged, CLR01 treatment reduced the appearance of motor problems and the formation of toxic protein clusters in the brain. Importantly, the team showed that in much older animals with more progressed Parkinson’s, CLR01 treatment was less effective.

This work shows that using protective therapies early on in Parkinson’s is essential for an effective treatment. These combined results highlight that CLR01 represents a candidate to treat Parkinson’s, and highlights the need for further research in this area.

Lead Researcher Dr Nora Bengoa-Vergniory said: “Future investment to determine the appropriate therapeutic window for these kinds of therapeutic agents is crucial for the success of these and other therapeutic strategies.”

Head of the Oxford Parkinson’s Disease Centre and senior author on the study Professor Richard Wade-Martins said: “Our work is focused on developing new approaches to saving neurons when they start to lose function early on, but before they die later on in the condition. This is a very exciting piece of work showing that drug treatments can be developed to unpick toxic protein clusters to save neurons in models of Parkinson’s. This work should give encouragement to those ultimately hoping for protective therapies.”

Dr Beckie Port, Research Manager at Parkinson’s UK, said: "We desperately need treatments that protect brain cells in Parkinson's. These findings show that this innovative 'molecular tweezer' approach has exciting potential in the lab. We now need to take this therapy forward to test in clinical trials - only then will we know whether it can do the same in people with Parkinson's."

 

The research paper “CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s disease is published in Nature Communications.

This story has been featured in The Times: "Brain 'tweezers' could treat Parkinson's".

Similar stories

Iron deficiency anaemia in early pregnancy increases risk of heart defects, suggests new research

In animal models, iron deficient mothers have a greatly increased risk of having offspring with congenital heart disease (CHD). The risk of CHD can be greatly reduced if the mother is given iron supplements very early in pregnancy. Additionally, embryos from a mouse model of Down Syndrome were particularly vulnerable to the effects of maternal iron deficiency, leading to a higher risk of developing severe heart defects.

The only way is UPP!

The OPDC is delighted to announce that Parkinson’s UK have agreed to fund a further four and a half years of ODPC Discovery Cohort follow-up from August 2021.

New target to develop immunosuppressants

A new study from the Parekh Group has resolved a long-standing question in our understanding of intracellular Ca2+ signalling, namely how a specific type of Ca2+ channel is uniquely able to signal to the nucleus to regulate gene expression. By unravelling this mechanism, researchers have identified a new approach for developing immunosuppressant drugs.

How the kidney contributes to healthy iron levels and disease

A new study from the Lakhal-Littleton Group has addressed a long-standing gap in our understanding of systemic iron homeostasis. It provides the first formal demonstration that the hormone hepcidin controls iron reabsorption in the kidney, in a manner that impacts the body’s iron levels, under normal physiological conditions. It also demonstrates for the first time how this mechanism becomes critically important in the development of iron disorders.

New research to radically alter our understanding of synaptic development

A new study from the Molnár group on the role of regulated synaptic vesicular release in specialised synapse formation has made it to the cover of Cerebral Cortex.